×

Hedge Funds Carl Icahn

  • Carl Icahn

    Democrats' call to probe Carl Icahn came after former White House ethics lawyers had warned about his role advising President Trump.

  • "We are writing to request that your agencies investigate whether Carl Icahn violated insider trading laws, anti-market manipulation laws, or any other relevant laws based on his recent actions in the market for renewable fuel credits," the senators said in a letter to the heads of the Securities and Exchange Commission, the Commodity Futures Trading...

  • Carl Icahn

    Eight Democratic Senators on Tuesday asked US regulators to launch a probe into Carl Icahn's activities in the US biofuels blending market. CNBC's 'Power Lunch' crew reacts to the news.

  • Since then, billionaire investor Carl Icahn, Hertz's biggest shareholder, has increased his stake in the company, and the company's former CEO, John Tague, has been replaced by Marinello. The company's net loss from continuing operations widened to $223 million, or $2.69 per share, in the first quarter ended March 31, from $52 million, or 61 cents per share, a year...

  • NEW YORK, May 8- Activist investor Keith Meister revealed his fund's newest investment on Monday, detailing a bet on CenturyLink Inc and describing the telecom infrastructure company's pending purchase of Level 3 Communications Inc as "game changing" for the industry. Meister, speaking at the Sohn Conference in New York, said Corvex Management LP owns a 5.5...

  • Michael Dell

    Michael Dell started in his college dorm, became a multi-billionaire and fought off Carl Icahn. Here's how he did it.

  • BEVERLY HILLS, Calif., May 3- After years of discord with a prominent hedge-fund manager, a federal investigation and bad publicity, Herbalife Ltd Chief Executive Officer Michael Johnson is taking a victory lap. At the Milken Institute Global Conference this week, Johnson touted the wares of his nutritional supplement maker, offering free shakes and protein...

  • BEVERLY HILLS, Calif., May 3- After years of discord with a prominent hedge-fund manager, a federal investigation and bad publicity, Herbalife Ltd Chief Executive Officer Michael Johnson is taking a victory lap. At the Milken Institute Global Conference this week, Johnson touted the wares of his nutritional supplement maker, offering free shakes and protein...

  • AIG reported operating earnings of $1.37 billion, or $1.36 per share, compared with $765 million, or 64 cents per share, in the year-ago quarter. That easily beat Wall Street's average estimate of $1.08 per share, according to Thomson Reuters I/B/E/S. The New York- based insurer, which is the largest U.S. underwriter of commercial property and casualty policies,...

  • AIG reported operating earnings of $1.37 billion, or $1.36 per share, compared with $765 million, or 64 cents per share, in the year-ago quarter. The New York- based insurer also said its board authorized an additional $2.5 billion in share repurchases, putting the company closer to its goal of returning $25 billion of capital to investors by year-end.

  • Chief Executive Officer Peter Hancock said on March 9 he would depart once the board found a replacement, citing a lack of confidence among directors and investors. Chairman Douglas Steenland has said AIG's board remains committed to the existing turnaround effort. "We need to know" about the impending choice of CEO, said Sandler O'Neill analyst Paul Newsome.

  • Chief Executive Officer Peter Hancock said on March 9 he would depart once the board found a replacement, citing a lack of confidence among directors and investors. Chairman Douglas Steenland has said AIG's board remains committed to the existing turnaround effort. "We need to know" about the impending choice of CEO, said Sandler O'Neill analyst Paul Newsome.

  • Chief Executive Officer Peter Hancock announced on March 9 that he would depart once the board found a replacement, citing a lack of confidence among directors and investors. Chairman Douglas Steenland has said that AIG's board remains committed to the existing turnaround effort, but analysts are doubtful over whether a new CEO would carry out Hancock's...

  • Chief Executive Officer Peter Hancock announced on March 9 that he would depart once the board found a replacement, citing a lack of confidence among directors and investors. Chairman Douglas Steenland has said that AIG's board remains committed to the existing turnaround effort, but analysts are doubtful over whether a new CEO would carry out Hancock's...

  • Chief Executive Officer Peter Hancock announced on March 9 that he would depart once the board found a replacement, citing a lack of confidence among directors and investors. Chairman Douglas Steenland has said that AIG's board remains committed to the existing turnaround effort, but analysts are doubtful over whether a new CEO would carry out Hancock's...

  • NEW YORK, May 1- Carl Icahn's big bet on falling prices for biofuels credits generated a rare profit in that area last quarter for the billionaire investor's refining company CVR Energy, according to public filings. CVR Energy's refining unit posted a net gain of $6.4 million associated with the credits, a $50 million turnaround from the year-ago period when CVR...

  • NEW YORK, April 27- Strong growth from Bristol-Myers Squibb Co's Opdivo and Yervoy cancer immunotherapies drove the company's first-quarter results past analysts' expectations and relieved some anxiety about increasing competition for the drugs. "Sales for Opdivo were strong despite a more competitive landscape," Chief Executive Officer Giovanni...

  • NEW YORK, April 27- Bristol-Myers Squibb Co on Thursday reported higher-than-expected quarterly earnings, helped by increased sales of cancer drugs Opdivo and Yervoy and blood thinner Eliquis. Bristol-Myers shares were up 1.9 percent at $54.80 on the New York Stock Exchange. Bristol-Myers reported a profit of $1.57 billion, or 94 cents a share, for the quarter,...

  • NEW YORK, April 27- Bristol-Myers Squibb Co on Thursday posted better-than-expected first-quarter earnings, helped by growth from cancer drugs Opdivo and Yervoy and blood thinner Eliquis. Bristol-Myers reported profit of $1.57 billion, or 94 cents a share, in the quarter, up from $1.20 billion, or 71 cents a share, a year earlier. Wall Street analysts, on average,...

  • In one example of a change in strategy, Neuberger Berman sounded out hedge funds about investing in Whole Foods Market and pressing for change.